EQRx wants to turn drug pricing reform on its head. Can it succeed, or will Big Pharma stop it in its tracks?

Max Gelman

Senior Editor

Drug pricing reform has been a political football for years, with both Donald Trump and Joe Biden championing changes during their presidencies. Little has moved …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EQRx wants to turn drug pricing reform on its head. Can it succeed, or will Big Pharma stop it in its tracks?

Max Gelman

Senior Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Biotech seed rounds sink to lowest level in years as industry slump drags on

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

Pharma's wins and losses in Trump's sprawling executive order on drug prices

US drugs rely heavily on ingredients made overseas, new report shows

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

EQRx wants to turn drug pric­ing re­form on its head. Can it suc­ceed, or will Big Phar­ma stop it in its tracks?

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

EQRx wants to turn drug pricing reform on its head. Can it succeed, or will Big Pharma stop it in its tracks?